Clinical Trial Detail

NCT ID NCT03391869
Title Phase III Trial of (LCT) After Nivolumab and Ipilimumab
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Ipilimumab + Nivolumab

Age Groups: adult senior

Additional content available in CKB BOOST